HER-2as a target for breast cancer therapy

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 1848-1852

  Ignatiadis, Michail ^a   Desmedt, Christine ^a   Sotiriou, Christos ^a   De Azambuja, Evandro ^a   Piccart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; TANESPIMYCIN; TAXANE DERIVATIVE; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; FEMALE; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 63549143099     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1844     Document Type: Article

References (38)

1. Coussens L, Yang-Feng TL, LiaoYC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science1985;230:1132-9.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb B-related gene in a human mammary carcinoma. Science 1985;229:974-6.
3. Slamon DJ, Clark GM,Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987;235:177-82.
4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol 2007; 25: 118-45.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341 -54.
6. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995;378: 394-8.
7. Baselga J, Norton L,Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825-31.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 + /MBC) markedly increases anticancer activity: a randomised, multinational controlled phase III trial. J Clin Oncol Suppl 1998;16:abstract 377.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72.
11. Romond EH, Perez EA, BryantJ, et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-84.
12. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol Suppl 2007;25: abstract 512.
13. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positivebreastcancer: a randomised controlled trial. Lancet2007;369:29-36.
14. Slamon D, EiermannW, Robert N, etal. BCIRG 006: 2nd interim analysis phase III randomized trial com-
15. 2/neu positive early breast cancer patients. Breast Cancer ResTreat Suppl 2006;100: abstract 52.
16. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-20.
17. Spielmann M,RocheH, HumbletY, etal. 3-Year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: results of the PACS-04 trial. Breast Cancer Res Treat Suppl 2007;106:abstract 72.
18. Piccart M. Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer.Clin Breast Cancer 2008;8:S100-113.
19. Perez EA, Suman VG, Davidson N, Martino S, Kaufman P. Slide presentation at the 41st American Society of Clinical OncologyAnnual Meeting; 2005.
20. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25: 3859-65.
21. Rastogi P,Jeong J,Geyer CE, et al. Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab(H). J Clin Oncol Suppl 2007; 25: abstract LBA513.
22. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central CancerTreatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26: 1231-8.
23. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358: 1409-11.
24. Vanden BI, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 2008;26:4869 -74.
25. Korkaya H, Paulson A, Iovino F,Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-30.
26. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672 -9.
27. Musolino A, Naldi N, BortesiB,etal. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789 -96.
28. Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA-positivecirculating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J Clin Oncol 2007;25:5194-202.
29. Bozionellou V, Mavroudis D, Perraki M, et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004;10:8185 -94.
30. Baselga J, Cameron D, Miles D, et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol Suppl 2008;25:abstract 1004.
31. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733 -43.
32. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12: 395-402.
33. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117 -27.
34. Paik S. Controversies in ER and HER2 testing. Presented at the 5th Annual International Congress on the Future of Breast Cancer; Koala Coast, HI; 2006.
35. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS. The efficacy of Herceptin therapies is influenced by the expression of other erb β receptors,their ligands and the activation of downstream signalling proteins. Br J Cancer 2004; 91: 1190-4.
36. Pegram M, Chan D, Dichmann RA, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat Suppl 2006;100: abstract 301.
37. Mackey J, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormonedependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat Suppl 2006;100: abstract 3.
38. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose- escalation study. J Clin Oncol 2007;25:5410-7.